Sfoglia per Autore
Immune checkpoint blockade in malignant mesothelioma: A novel therapeutic strategy against a deadly disease?
2014 Calabro', L; Maio, M.
Efficacy and safety of ipilimumab 3mg/kg in patients with pretreated, metastatic, mucosal melanoma
2014 Del Vecchio, M; Di Guardo, L; Ascierto, Pa; Grimaldi, Am; Sileni, Vc; Pigozzo, J; Ferraresi, V; Nuzzo, C; Rinaldi, G; Testori, A; Ferrucci, Pf; Marchetti, P; De Galitiis, F; Queirolo, P; Tornari, E; Marconcini, R; Calabro', L; Maio, M.
Ipilimumab retreatment in patients with pretreated advanced melanoma: the expanded access programme in Italy
2014 Chiarion-Sileni, V; Pigozzo, J; Ascierto, Pa; Simeone, E; Maio, M; Calabro', L; Marchetti, P; De Galitiis, F; Testori, A; Ferrucci, Pf; Queirolo, P; Spagnolo, F; Quaglino, P; Carnevale Schianca, F; Mandalà, M; Di Guardo, L; Del Vecchio, M.
Biomarkers for immune checkpoint inhibitors--authors' reply
2014 Calabro', L; Maio, M.
CTLA4 blockade in mesothelioma: finally a competing strategy over cytotoxic/target therapy?
file con accesso da definire2015 Calabro', L; Ceresoli, Gl; di Pietro, A; Cutaia, O; Morra, A; Ibrahim, R; Maio, M.
Three-year follow-up of advanced melanoma patients who received ipilimumab plus fotemustine in the Italian Network for Tumor Biotherapy (NIBIT)-M1 phase II study
2015 Di Giacomo, Am; Ascierto, Pa; Queirolo, P; Pilla, L; Ridolfi, R; Santinami, M; Testori, A; Simeone, E; Guidoboni, M; Maurichi, A; Orgiano, L; Spadola, G; Del Vecchio, M; Danielli, R; Calabro', L; Annesi, D; Giannarelli, D; Maccalli, C; Fonsatti, E; Parmiani, G; Maio, M.
Immune checkpoint blockade in malignant mesothelioma
file con accesso da definire2015 Calabro', L; Maio, M.
Cancer Bio-Immunotherapy in Siena": Eleventh Meeting of the Network Italiano per la Bioterapia dei Tumori (NIBIT), Siena, Italy, October 17-19, 2013
file con accesso da definire2015 Calabro', Luana
Anticancer immunotherapy by CTLA-4 blockade: obligatory contribution of IL-2 receptors and negative prognostic impact of soluble CD25
file con accesso da definire2015 Hannani, D; Vétizou, M; Enot, D; Rusakiewicz, S; Chaput, N; Klatzmann, D; Desbois, M; Jacquelot, N; Vimond, N; Chouaib, S; Mateus, C; Allison, Jp; Ribas, A; Wolchok, Jd; Yuan, J; Wong, P; Postow, M; Mackiewicz, A; Mackiewicz, J; Schadendorff, D; Jaeger, D; Zörnig, I; Hassel, J; Korman, Aj; Bahjat, K; Maio, M; Calabro', L; Teng, Mw; Smyth, Mj; Eggermont, A; Robert, C; Kroemer, G; Zitvogel, L.
Efficacy and safety of an intensified schedule of tremelimumab for chemotherapy-resistant malignant mesothelioma: an open-label, single-arm, phase 2 study
2015 Calabro', L; Morra, A; Fonsatti, E; Cutaia, O; Fazio, C; Annesi, D; Lenoci, M; Amato, G; Danielli, R; Altomonte, M; Giannarelli, D; Di Giacomo, Am; Maio, M.
Tremelimumab as second- or third-line treatment of unresectable malignant mesothelioma (MM): Results from the global, double-blind, placebo-controlled DETERMINE study
file con accesso da definire2016 Kindler, Hl; Scherpereel, A; Calabro', L; Aerts, J; Perez, Sc; Bearz, A; Nackaerts, K; Fennell, Da; Kowalski, D; Tsao, As; Taylor, P; Grosso, F; Antonia, Sj; Nowak, Ak; Ibrahim, Ra; Taboada, M; Puglisi, M; Stockman, Pk; Maio, M
"Cancer Bio-Immunotherapy in Siena": Thirteenth Meeting of the Network Italiano per la Bioterapia dei Tumori (NIBIT), Siena, Italy, October 8-10, 2015
file con accesso da definire2016 Maio, M; Bertocci, E; Fazio, C; Chiarucci, C; Cutaia, O; Scala, E; Giacobini, G; Lofiego, Mf; Fonsatti, E; Maccalli, C; Nicolay, Hj; Parmiani, G; Nibit, ; and collaborators (Anichini, A; Di Giacomo, Am; Sica, A; Calcinotto, A; Seliger, B; Buccione, C; Garlanda, C; Martinoli, C; Pozzi, C; Huber, C; Chartash, E; Carbone, E; Marincola, Fm; Zuccolotto, G; Schuler, G; Oliveira, G; Corna, G; Rammensee, Hg; Cuillerot, Jm; Rivoltini, L; Moretta, L; Calabro', L; Tagliamonte, M; Figini, M; Squadrito, Ml; Colombo, Mp; Giordano, M; Azab, M; Nistico', P; Thor Straten, P; Coulie, P; Ibrahim, R; Huber, S; Monfardini, S; Ferrone, S; Sahin, U; Bronte, V; Fridman, Wh; Trajanoski Z., )
Italian cohort of nivolumab Expanded Access Programme (EAP): efficacy and safety data from a real-world population
2016 Crino, L; Bidoli, P; Delmonte, A; Grossi, F; de Marinis, F; Sperandi, F; Piantedosi, F; Vitali, M; Parra, Hs; Scagnoli, S; Minuti, G; Calabro', L; Tiseo, M; Turci, D; Quadrini, S; Antonelli, P; Manzo, A; Prediletto, I; Giannarelli, D; Galetta, D
Cancer Bio-Immunotherapy in Siena": Twelfth Meeting of the Network Italiano per la Bioterapia dei Tumori (NIBIT), Siena, Italy, October 9-11, 2014
file con accesso da definire2016 Maio, M; Bertocci, E; Pilla, L; Fazio, C; Chiarucci, C; Cutaia, O; Fonsatti, E; Maccalli, C; Parmiani, G; Mondino, A; Robbins, Pf; Angelova, M; Stassi, G; Cioffi, M; Cavallo, F; Pellegatta, S; Sangiolo, D; Russo, V; Protti, Mp; Tripodo, C; Marchesi, F; Di Mitri, D; Ferrini, S; Bedognetti, D; Marincola, Fm; Fridman, Wh; Seliger, B; Cappuzzello, E; Moschella, F; Romero, P; Figdor, Cg; Griffiths, Ea; Aurisicchio, L; Weber, J; Calabro', L; Tumori, T; Ibrahim, R; Ferrè, P; Fabre, P; Del Vecchio, M; Tumori, N; Ramazzotti, M; Weide, B; Giannarelli, D; Elena, Tr; Guidoboni, M; Buonaguro, L; Tumori, Cd; Di Giacomo, Am.
ICOS Expression as Immunologic Marker in Immune Activating Monoclonal Antibodies
file con accesso da definire2016 Danielli, R; Cutaia, O; Fazio, C; Bertocci, E; Fonsatti, E; Maio, M; Calabro', L
Goals and objectives of the Italian Network for Tumor Biotherapy (NIBIT)
file con accesso da definire2017 Russo, V; Amadori, A; Bregni, M; Calabro', L; Colombo, Mp; Di Nicola, M; Ferrucci, Pf; Proietti, E; Maio, M; Bellone, M.
Tremelimumab as second-line or third-line treatment in relapsed malignant mesothelioma (DETERMINE): a multicentre, international, randomised, double-blind, placebo-controlled phase 2b trial
file con accesso da definire2017 Maio, M; Scherpereel, A; Calabro', L; Aerts, J; Perez, Sc; Bearz, A; Nackaerts, K; Fennell, Da; Kowalski, D; Tsao, As; Taylor, P; Grosso, F; Antonia, Sj; Nowak, Ak; Taboada, M; Puglisi, M; Stockman, Pk; Kindler, Hl.
Soluble NKG2D ligands are biomarkers associated with the clinical outcome to immune checkpoint blockade therapy of metastatic melanoma patients
file con accesso da definire2017 Maccalli, C; Giannarelli, D; Chiarucci, C; Cutaia, O; Giacobini, G; Hendrickx, W; Amato, G; Annesi, D; Bedognetti, D; Altomonte, M; Danielli, R; Calabro', L; Di Giacomo, Am; Marincola, Fm; Parmiani, G; Maio, M.
Immune checkpoint therapy of mesothelioma: Pre-clinical bases and clinical evidences
file con accesso da definire2017 Calabro', L; Ceresoli, Gl; D'Incecco, A; Scherpereel, A; Aerts, J; Maio, M.
Prevalence of hypophysitis in a cohort of patients with metastatic melanoma and prostate cancer treated with ipilimumab
file con accesso da definire2017 Brilli, L; Danielli, R; Ciuoli, C; Calabro', L; Di Giacomo, Am; Cerase, A; Paffetti, P; Sestini, F; Porcelli, B; Maio, M; Pacini, F.
| Titolo | Data di pubblicazione | Autore(i) | File |
|---|---|---|---|
| Immune checkpoint blockade in malignant mesothelioma: A novel therapeutic strategy against a deadly disease? | 2014 | Calabro', L; Maio, M. | |
| Efficacy and safety of ipilimumab 3mg/kg in patients with pretreated, metastatic, mucosal melanoma | 2014 | Del Vecchio, M; Di Guardo, L; Ascierto, Pa; Grimaldi, Am; Sileni, Vc; Pigozzo, J; Ferraresi, V; N...uzzo, C; Rinaldi, G; Testori, A; Ferrucci, Pf; Marchetti, P; De Galitiis, F; Queirolo, P; Tornari, E; Marconcini, R; Calabro', L; Maio, M. | |
| Ipilimumab retreatment in patients with pretreated advanced melanoma: the expanded access programme in Italy | 2014 | Chiarion-Sileni, V; Pigozzo, J; Ascierto, Pa; Simeone, E; Maio, M; Calabro', L; Marchetti, P; De ...Galitiis, F; Testori, A; Ferrucci, Pf; Queirolo, P; Spagnolo, F; Quaglino, P; Carnevale Schianca, F; Mandalà, M; Di Guardo, L; Del Vecchio, M. | |
| Biomarkers for immune checkpoint inhibitors--authors' reply | 2014 | Calabro', L; Maio, M. | |
| CTLA4 blockade in mesothelioma: finally a competing strategy over cytotoxic/target therapy? | 2015 | Calabro', L; Ceresoli, Gl; di Pietro, A; Cutaia, O; Morra, A; Ibrahim, R; Maio, M. | file con accesso da definire |
| Three-year follow-up of advanced melanoma patients who received ipilimumab plus fotemustine in the Italian Network for Tumor Biotherapy (NIBIT)-M1 phase II study | 2015 | Di Giacomo, Am; Ascierto, Pa; Queirolo, P; Pilla, L; Ridolfi, R; Santinami, M; Testori, A; Simeon...e, E; Guidoboni, M; Maurichi, A; Orgiano, L; Spadola, G; Del Vecchio, M; Danielli, R; Calabro', L; Annesi, D; Giannarelli, D; Maccalli, C; Fonsatti, E; Parmiani, G; Maio, M. | |
| Immune checkpoint blockade in malignant mesothelioma | 2015 | Calabro', L; Maio, M. | file con accesso da definire |
| Cancer Bio-Immunotherapy in Siena": Eleventh Meeting of the Network Italiano per la Bioterapia dei Tumori (NIBIT), Siena, Italy, October 17-19, 2013 | 2015 | Calabro', Luana | file con accesso da definire |
| Anticancer immunotherapy by CTLA-4 blockade: obligatory contribution of IL-2 receptors and negative prognostic impact of soluble CD25 | 2015 | Hannani, D; Vétizou, M; Enot, D; Rusakiewicz, S; Chaput, N; Klatzmann, D; Desbois, M; Jacquelot, ...N; Vimond, N; Chouaib, S; Mateus, C; Allison, Jp; Ribas, A; Wolchok, Jd; Yuan, J; Wong, P; Postow, M; Mackiewicz, A; Mackiewicz, J; Schadendorff, D; Jaeger, D; Zörnig, I; Hassel, J; Korman, Aj; Bahjat, K; Maio, M; Calabro', L; Teng, Mw; Smyth, Mj; Eggermont, A; Robert, C; Kroemer, G; Zitvogel, L. | file con accesso da definire |
| Efficacy and safety of an intensified schedule of tremelimumab for chemotherapy-resistant malignant mesothelioma: an open-label, single-arm, phase 2 study | 2015 | Calabro', L; Morra, A; Fonsatti, E; Cutaia, O; Fazio, C; Annesi, D; Lenoci, M; Amato, G; Danielli..., R; Altomonte, M; Giannarelli, D; Di Giacomo, Am; Maio, M. | |
| Tremelimumab as second- or third-line treatment of unresectable malignant mesothelioma (MM): Results from the global, double-blind, placebo-controlled DETERMINE study | 2016 | Kindler, Hl; Scherpereel, A; Calabro', L; Aerts, J; Perez, Sc; Bearz, A; Nackaerts, K; Fennell, D...a; Kowalski, D; Tsao, As; Taylor, P; Grosso, F; Antonia, Sj; Nowak, Ak; Ibrahim, Ra; Taboada, M; Puglisi, M; Stockman, Pk; Maio, M | file con accesso da definire |
| "Cancer Bio-Immunotherapy in Siena": Thirteenth Meeting of the Network Italiano per la Bioterapia dei Tumori (NIBIT), Siena, Italy, October 8-10, 2015 | 2016 | Maio, M; Bertocci, E; Fazio, C; Chiarucci, C; Cutaia, O; Scala, E; Giacobini, G; Lofiego, Mf; Fon...satti, E; Maccalli, C; Nicolay, Hj; Parmiani, G; Nibit, ; and collaborators (Anichini, A; Di Giacomo, Am; Sica, A; Calcinotto, A; Seliger, B; Buccione, C; Garlanda, C; Martinoli, C; Pozzi, C; Huber, C; Chartash, E; Carbone, E; Marincola, Fm; Zuccolotto, G; Schuler, G; Oliveira, G; Corna, G; Rammensee, Hg; Cuillerot, Jm; Rivoltini, L; Moretta, L; Calabro', L; Tagliamonte, M; Figini, M; Squadrito, Ml; Colombo, Mp; Giordano, M; Azab, M; Nistico', P; Thor Straten, P; Coulie, P; Ibrahim, R; Huber, S; Monfardini, S; Ferrone, S; Sahin, U; Bronte, V; Fridman, Wh; Trajanoski Z., ) | file con accesso da definire |
| Italian cohort of nivolumab Expanded Access Programme (EAP): efficacy and safety data from a real-world population | 2016 | Crino, L; Bidoli, P; Delmonte, A; Grossi, F; de Marinis, F; Sperandi, F; Piantedosi, F; Vitali, M...; Parra, Hs; Scagnoli, S; Minuti, G; Calabro', L; Tiseo, M; Turci, D; Quadrini, S; Antonelli, P; Manzo, A; Prediletto, I; Giannarelli, D; Galetta, D | |
| Cancer Bio-Immunotherapy in Siena": Twelfth Meeting of the Network Italiano per la Bioterapia dei Tumori (NIBIT), Siena, Italy, October 9-11, 2014 | 2016 | Maio, M; Bertocci, E; Pilla, L; Fazio, C; Chiarucci, C; Cutaia, O; Fonsatti, E; Maccalli, C; Parm...iani, G; Mondino, A; Robbins, Pf; Angelova, M; Stassi, G; Cioffi, M; Cavallo, F; Pellegatta, S; Sangiolo, D; Russo, V; Protti, Mp; Tripodo, C; Marchesi, F; Di Mitri, D; Ferrini, S; Bedognetti, D; Marincola, Fm; Fridman, Wh; Seliger, B; Cappuzzello, E; Moschella, F; Romero, P; Figdor, Cg; Griffiths, Ea; Aurisicchio, L; Weber, J; Calabro', L; Tumori, T; Ibrahim, R; Ferrè, P; Fabre, P; Del Vecchio, M; Tumori, N; Ramazzotti, M; Weide, B; Giannarelli, D; Elena, Tr; Guidoboni, M; Buonaguro, L; Tumori, Cd; Di Giacomo, Am. | file con accesso da definire |
| ICOS Expression as Immunologic Marker in Immune Activating Monoclonal Antibodies | 2016 | Danielli, R; Cutaia, O; Fazio, C; Bertocci, E; Fonsatti, E; Maio, M; Calabro', L | file con accesso da definire |
| Goals and objectives of the Italian Network for Tumor Biotherapy (NIBIT) | 2017 | Russo, V; Amadori, A; Bregni, M; Calabro', L; Colombo, Mp; Di Nicola, M; Ferrucci, Pf; Proietti, ...E; Maio, M; Bellone, M. | file con accesso da definire |
| Tremelimumab as second-line or third-line treatment in relapsed malignant mesothelioma (DETERMINE): a multicentre, international, randomised, double-blind, placebo-controlled phase 2b trial | 2017 | Maio, M; Scherpereel, A; Calabro', L; Aerts, J; Perez, Sc; Bearz, A; Nackaerts, K; Fennell, Da; K...owalski, D; Tsao, As; Taylor, P; Grosso, F; Antonia, Sj; Nowak, Ak; Taboada, M; Puglisi, M; Stockman, Pk; Kindler, Hl. | file con accesso da definire |
| Soluble NKG2D ligands are biomarkers associated with the clinical outcome to immune checkpoint blockade therapy of metastatic melanoma patients | 2017 | Maccalli, C; Giannarelli, D; Chiarucci, C; Cutaia, O; Giacobini, G; Hendrickx, W; Amato, G; Annes...i, D; Bedognetti, D; Altomonte, M; Danielli, R; Calabro', L; Di Giacomo, Am; Marincola, Fm; Parmiani, G; Maio, M. | file con accesso da definire |
| Immune checkpoint therapy of mesothelioma: Pre-clinical bases and clinical evidences | 2017 | Calabro', L; Ceresoli, Gl; D'Incecco, A; Scherpereel, A; Aerts, J; Maio, M. | file con accesso da definire |
| Prevalence of hypophysitis in a cohort of patients with metastatic melanoma and prostate cancer treated with ipilimumab | 2017 | Brilli, L; Danielli, R; Ciuoli, C; Calabro', L; Di Giacomo, Am; Cerase, A; Paffetti, P; Sestini, ...F; Porcelli, B; Maio, M; Pacini, F. | file con accesso da definire |
Legenda icone
- file ad accesso aperto
- file disponibili solo agli amministratori
- file sotto embargo
- nessun file disponibile